Chief Executive Officer

Chief Legal & Pub. Affairs Off

Director

DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Institution	Shares	Value	Change
BERKSHIRE HATHAWAY INC	30,100,585	$4.6B	DECREASED
BlackRock, Inc.	2,766,751	$425M	DECREASED
VANGUARD CAPITAL MANAGEMENT LLC	2,180,225	$335M	NEW
MORGAN STANLEY	1,666,038	$256M	INCREASED
VANGUARD PORTFOLIO MANAGEMENT LLC	1,479,600	$227M	NEW

Insider	Type	Shares	Value	Date
Javier Rodriguez (Chief Executive Officer)	SELL	39,407	$8M	2026-06-15
Javier Rodriguez (Chief Executive Officer)	SELL	30,000	$6M	2026-06-15
Kathleen Alyce Waters (Chief Legal & Pub. Affairs Off)	SELL	6,455	$1M	2026-06-15
Kathleen Alyce Waters (Chief Legal & Pub. Affairs Off)	SELL	8,950	$2M	2026-06-15
Phyllis R Yale (Director)	GIFT	5,038		2026-05-26

DaVita Inc. (DVA) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades